Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.
about
Contemporary clinical management of the cerebral complications of preeclampsiaAlternative magnesium sulphate regimens for women with pre-eclampsia and eclampsiaAlternative magnesium sulphate regimens for women with pre-eclampsia and eclampsiaDiagnosis and management of preeclampsia in community settings in low and middle-income countriesClinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsiaEconomic Evaluation alongside Multinational Studies: A Systematic Review of Empirical StudiesOutcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia: a systematic review.Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules.Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters.Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting.Should magnesium sulfate be administered to women with mild pre-eclampsia? A systematic review of published reports on eclampsia.Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments.Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol.SUPPORT Tools for evidence-informed health Policymaking (STP) 12: Finding and using research evidence about resource use and costs.Alternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia: a systematic review of non-randomized studies.Incorporating considerations of resources use into grading recommendations.Optimizing treatment for the prevention of pre-eclampsia/eclampsia in Nepal: is calcium supplementation during pregnancy cost-effective?Pre-eclampsia, severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelets syndrome: what is new?Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology.An economic analysis of immediate delivery and expectant monitoring in women with hypertensive disorders of pregnancy, between 34 and 37 weeks of gestation (HYPITAT-II).Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT.The valuation of prenatal life in economic evaluations of perinatal interventions.Economic assessment of screening for pre-eclampsia.Critical care management of eclamptics: challenges in an African setting.Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey.Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia.An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre-eclampsia at term (HYPITAT trial).Cost effectiveness of medical devices to diagnose pre-eclampsia in low-resource settings.Current and Future Challenges for Collaborative Computational Technologies for the Life Sciences
P2860
Q21128665-7C5D87FB-3F8B-4EA5-B91E-A0141A6E20D1Q24236555-0EF2197E-380C-44E5-8706-F62A465BFCDFQ24242325-1DF0BB22-2CF2-4CD2-9600-A19BA1CD0D27Q26764860-870661DB-5CB3-46C2-AA81-30418E2E1D56Q26776342-AA641F75-71B4-4A48-8AE6-C6DB099EDA59Q28083366-1639A355-DA60-44D3-9A43-4CAA22BFAFABQ30234715-D6CEC4EE-0265-47AD-998C-A6BDD9B6DB8FQ33606843-C49F0EBC-CFE2-43E4-BDE6-EFF8A8B6D9AEQ35564876-C666B728-F9AC-49DE-8BE4-C39D812CF30FQ35590950-AD378CAC-1D1F-4D4B-B477-EA5E4F8A28CDQ35592565-F9D59AD3-9FDD-45A5-9E2A-5A7452D9DF9EQ35655056-11DC7663-B778-4B60-8D28-13CE3D703848Q35655263-EEF97A1F-3C5B-497A-B83F-8BC4C6C21B04Q35734439-786CD816-1F8A-4ED8-9C15-38BC41089A8FQ35814624-C4DC1B7D-9B48-4F7D-9627-AA875E9CB886Q36672034-8E18B652-C339-4A07-A869-6688A2395804Q37539730-6432B1E6-FCA4-4809-AE67-E4A865FE411DQ37924287-FC695B52-5CBA-450C-8515-C7F695DD0B36Q38068886-D25A0F6E-5CC1-4B52-9B70-4167F0B3E2BFQ38694952-12B12F6E-BC01-48F6-8901-DF124E552F26Q40858287-25ADCFF9-EEDC-4992-B258-1F3F73FA84D1Q41267211-D63C6939-8277-4757-9700-C6539BBA836FQ45299906-6CFE603A-DD18-4C18-BD27-4FD708B4DEE6Q46325309-D6A334BC-4658-4FAC-B022-06379DE1D6A0Q46337071-F453A447-8FE9-43F4-B7CA-AF6C565069F0Q47116099-5B25B9FB-F99D-4941-8420-E84E5812529FQ47259219-766BBA8B-E4AD-4B72-8A8B-79E36AAF6AC9Q51752080-4B8EDE94-463B-4560-9B05-F045745F4F83Q52404727-806AE2E9-1E9F-4EC8-8CD7-E689CEF865DDQ56399692-D947560E-7BFB-4EAA-B629-A3D608DBEEC4
P2860
Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@en
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@nl
type
label
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@en
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@nl
prefLabel
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@en
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@nl
P2093
P2860
P1476
Cost-effectiveness of prophyla ...... valuation of the Magpie Trial.
@en
P2093
Alastair Gray
Judit Simon
Magpie Trial Collaborative Group
P2860
P304
P356
10.1111/J.1471-0528.2005.00785.X
P50
P577
2006-02-01T00:00:00Z